{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:25:48Z","timestamp":1782854748086,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004035","name":"Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["20140204"],"award-info":[{"award-number":["20140204"]}],"id":[{"id":"10.13039\/501100004035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Breast cancer risk, development, and treatment are influenced by genetic variation in certain genes, namely those involved in cell proliferation, tumor suppression, and drug metabolism. In turn, the relevance of the aforementioned genetic variation to cancer depends on the ethnic group in question, highlighting the need for population-specific association studies. Therefore, the objective of the present study was to investigate the association between certain <jats:italic>ESR1<\/jats:italic>, <jats:italic>ESR2<\/jats:italic>, <jats:italic>HER2<\/jats:italic>, <jats:italic>UGT1A4<\/jats:italic>, and <jats:italic>UGT2B7<\/jats:italic> single nucleotide polymorphisms and breast cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Blood samples were collected from 437 Jordanian-Arab breast cancer patients and healthy volunteers and subject to genotyping using the Sequenom MassARRAY\u00ae system (iPLEX GOLD).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Our findings show a significant association between breast cancer and the allelic (<jats:italic>P<\/jats:italic>\u2009=\u20090.02486879) and genotypic (<jats:italic>P<\/jats:italic>\u2009=\u20090.04793066) frequencies of the <jats:italic>ESR1<\/jats:italic> polymorphism rs3798577, a result which was confirmed in different genetic models. No other investigated polymorphism showed a significant association with breast cancer itself in Jordanian Arabs, but the Rare Hz (GG) vs Het (AG) genetic model revealed an association of the disease with the <jats:italic>ESR1<\/jats:italic> polymorphism rs3798577. However, several associations were found between certain polymorphisms and breast cancer\u2019s prognostic factors.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study suggests that certain polymorphisms may increase the risk of breast cancer in the Jordanian-Arab population. Future research and clinical translation could incorporate the current results in preventative breast cancer approaches tailored for Jordanian-Arab patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-019-6490-7","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T13:02:39Z","timestamp":1577710959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-0190","authenticated-orcid":false,"given":"Laith N.","family":"AL-Eitan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa M.","family":"Rababa\u2019h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour A.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rame H.","family":"Khasawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"6490_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/bcr921","volume":"6","author":"SE Hankinson","year":"2004","unstructured":"Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6:213. https:\/\/doi.org\/10.1186\/bcr921.","journal-title":"Breast Cancer Res"},{"key":"6490_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/J.CANLET.2011.11.022","volume":"327","author":"S Nowsheen","year":"2012","unstructured":"Nowsheen S, Aziz K, Panayiotidis MI, Georgakilas AG. Molecular markers for cancer prognosis and treatment: Have we struck gold? Cancer Lett. 2012;327:142\u201352. https:\/\/doi.org\/10.1016\/J.CANLET.2011.11.022.","journal-title":"Cancer Lett"},{"issue":"19","key":"6490_CR3","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.7150\/jca.33857","volume":"10","author":"L AL-Eitan","year":"2019","unstructured":"AL-Eitan L, Rababa\u2019h D, Alghamdi M, Khasawneh R. Correlation between candidate single nucleotide variants and several Clinicopathological risk factors related to breast Cancer in Jordanian women: a genotype-phenotype study. J Cancer. 2019;10(19):4647\u201354.","journal-title":"J Cancer"},{"key":"6490_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/07357907.2017.1289217","volume":"35","author":"AL-E LN","year":"2017","unstructured":"LN AL-E, Jamous RI, Khasawneh RH. Candidate gene analysis of breast Cancer in the Jordanian population of Arab descent: a case-control study. Cancer Investig. 2017;35:256\u201370. https:\/\/doi.org\/10.1080\/07357907.2017.1289217.","journal-title":"Cancer Investig"},{"key":"6490_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/jso.21856","volume":"105","author":"M Gage","year":"2012","unstructured":"Gage M, Wattendorf D, Henry LR. Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol. 2012;105:444\u201351. https:\/\/doi.org\/10.1002\/jso.21856.","journal-title":"J Surg Oncol"},{"key":"6490_CR6","doi-asserted-by":"publisher","first-page":"6743","DOI":"10.7314\/APJCP.2013.14.11.6743","volume":"14","author":"H Lu","year":"2014","unstructured":"Lu H, Chen D, Hu LP, et al. Estrogen receptor alpha gene polymorphisms and breast cancer risk: a case-control study with meta-analysis combined. Asian Pac J Cancer Prev. 2014;14:6743\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"6490_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/03602530903208652","volume":"42","author":"P Lazarus","year":"2010","unstructured":"Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev. 2010;42:182\u201394. https:\/\/doi.org\/10.3109\/03602530903208652.","journal-title":"Drug Metab Rev"},{"key":"6490_CR8","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1038\/s41598-018-25769-y","volume":"8","author":"BM Krishna","year":"2018","unstructured":"Krishna BM, Chaudhary S, Panda AK, et al. Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies. Sci Rep. 2018;8:7427. https:\/\/doi.org\/10.1038\/s41598-018-25769-y.","journal-title":"Sci Rep"},{"key":"6490_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1749-6632.2001.tb02725.x","volume":"952","author":"D Medina","year":"2001","unstructured":"Medina D, Sivaraman L, Hilsenbeck SG, et al. Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001;952:23\u201335.","journal-title":"Ann N Y Acad Sci"},{"key":"6490_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-010-0891-2","volume":"126","author":"K-D Yu","year":"2011","unstructured":"Yu K-D, Rao N-Y, Chen A-X, et al. A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Breast Cancer Res Treat. 2011;126:37\u201345. https:\/\/doi.org\/10.1007\/s10549-010-0891-2.","journal-title":"Breast Cancer Res Treat"},{"key":"6490_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-005-7697-7","volume":"94","author":"P Maguire","year":"2005","unstructured":"Maguire P, Margolin S, Skoglund J, et al. Estrogen receptor Beta (ESR2) polymorphisms in familial and sporadic breast Cancer. Breast Cancer Res Treat. 2005;94:145\u201352. https:\/\/doi.org\/10.1007\/s10549-005-7697-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"6490_CR12","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor positive breast cancer. Clin Cancer Res. 2014;20(7):1757\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2332.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"6490_CR13","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","volume":"73","author":"K Merenbakh-Lamin","year":"2013","unstructured":"Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mutation in estrogen receptor-\u03b1: a novel mechanism for acquired endocrine resistance in breast Cancer. Cancer Res. 2013;73(23):6856\u201364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1197.","journal-title":"Cancer Res"},{"issue":"12","key":"6490_CR14","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu Y-M, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446\u201351. https:\/\/doi.org\/10.1038\/ng.2823.","journal-title":"Nat Genet"},{"issue":"12","key":"6490_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, et al. ESR1 ligand binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439\u201345. https:\/\/doi.org\/10.1038\/ng.2822.","journal-title":"Nat Genet"},{"key":"6490_CR16","volume-title":"Molecular mechanisms of ErbB2-mediated breast Cancer Chemoresistance. In: Madame curie bioscience database [internet]","author":"M Tan","year":"2000","unstructured":"Tan M, Yu D. Molecular mechanisms of ErbB2-mediated breast Cancer Chemoresistance. In: Madame curie bioscience database [internet]. Austin (TX): Landes Bioscience; 2000-2013."},{"issue":"5","key":"6490_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s002390010043","volume":"50","author":"RA Tein","year":"2000","unstructured":"Tein RA, Staros JV. Evolutionary analysis of the ErbB receptor and ligand families. J Mol Evol. 2000;50(5):397\u2013412.","journal-title":"J Mol Evol"},{"issue":"4905","key":"6490_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707\u201312.","journal-title":"Science"},{"issue":"10 Suppl","key":"6490_CR19","first-page":"2199","volume":"53","author":"G Sauter","year":"1993","unstructured":"Sauter G, Moch H, Moore D, et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 1993;53(10 Suppl):2199\u2013203.","journal-title":"Cancer Res"},{"issue":"11","key":"6490_CR20","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/0277-5379(91)90012-3","volume":"27","author":"M Tateishi","year":"1991","unstructured":"Tateishi M, Ishida T, Mitsudomi T, et al. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 1991;27(11):1372\u20135.","journal-title":"Eur J Cancer"},{"issue":"1","key":"6490_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/bjc.1991.243","volume":"64","author":"NR Lemoine","year":"1991","unstructured":"Lemoine NR, Jain S, Silvestre F, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer. 1991;64(1):79\u201383.","journal-title":"Br J Cancer"},{"key":"6490_CR22","first-page":"1199","volume":"57","author":"M Tan","year":"1997","unstructured":"Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastatic potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199\u2013205.","journal-title":"Cancer Res"},{"issue":"6","key":"6490_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1535-6108(02)00212-X","volume":"2","author":"SE Moody","year":"2002","unstructured":"Moody SE, Sarkisian CJ, Hahn KT, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2(6):451\u201361.","journal-title":"Cancer Cell"},{"key":"6490_CR24","doi-asserted-by":"publisher","first-page":"e0132269","DOI":"10.1371\/journal.pone.0132269","volume":"10","author":"A Romero-Lorca","year":"2015","unstructured":"Romero-Lorca A, Novillo A, Gaibar M, et al. Impacts of the Glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen metabolism in breast Cancer patients. PLoS One. 2015;10:e0132269. https:\/\/doi.org\/10.1371\/journal.pone.0132269.","journal-title":"PLoS One"},{"key":"6490_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-009-0532-9","volume":"121","author":"N Li","year":"2010","unstructured":"Li N, Dong J, Hu Z, et al. Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;121:177\u201384. https:\/\/doi.org\/10.1007\/s10549-009-0532-9.","journal-title":"Breast Cancer Res Treat"},{"key":"6490_CR26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/J.CANEP.2015.08.011","volume":"39","author":"Y Su","year":"2015","unstructured":"Su Y, Jiang Y, Sun S, et al. Effects of HER2 genetic polymorphisms on its protein expression in breast cancer. Cancer Epidemiol. 2015;39:1123\u20137. https:\/\/doi.org\/10.1016\/J.CANEP.2015.08.011.","journal-title":"Cancer Epidemiol"},{"key":"6490_CR27","doi-asserted-by":"publisher","first-page":"e22406","DOI":"10.1002\/jcla.22406","volume":"32","author":"FC De Almeida","year":"2018","unstructured":"De Almeida FC, Banin Hirata BK, Ariza CB, et al. HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility. J Clin Lab Anal. 2018;32:e22406. https:\/\/doi.org\/10.1002\/jcla.22406.","journal-title":"J Clin Lab Anal"},{"key":"6490_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s40262-016-0402-7","volume":"55","author":"N Sutiman","year":"2016","unstructured":"Sutiman N, Lim JSL, Muerdter TE, et al. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on Tamoxifen disposition in Asian breast Cancer patients. Clin Pharmacokinet. 2016;55:1239\u201350. https:\/\/doi.org\/10.1007\/s40262-016-0402-7.","journal-title":"Clin Pharmacokinet"},{"key":"6490_CR29","doi-asserted-by":"publisher","first-page":"e97522","DOI":"10.1371\/journal.pone.0097522","volume":"9","author":"L Jing","year":"2014","unstructured":"Jing L, Su L, Ring BZ. Ethnic background and genetic variation in the evaluation of cancer risk: a systematic review. PLoS One. 2014;9:e97522. https:\/\/doi.org\/10.1371\/journal.pone.0097522.","journal-title":"PLoS One"},{"key":"6490_CR30","volume-title":"Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence","author":"KJ Preacher","year":"2001","unstructured":"Preacher KJ. Calculation for the chi-square test: an interactive calculation tool for chi-square tests of goodness of fit and independence. 2001. http:\/\/quantpsy.org\/chisq\/chisq.htm. Accessed 19 Oct 2018."},{"key":"6490_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.hdy.6800717","volume":"95","author":"J Li","year":"2005","unstructured":"Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95:221\u20137.","journal-title":"Heredity"},{"key":"6490_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1086\/383251","volume":"74","author":"DR Nyholt","year":"2004","unstructured":"Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74:765\u20139.","journal-title":"Am J Hum Genet"},{"key":"6490_CR33","doi-asserted-by":"publisher","first-page":"7757","DOI":"10.2147\/OTT.S207255","volume":"12","author":"L AL-Eitan","year":"2019","unstructured":"AL-Eitan L, Rababa\u2019h D, Alghamdi M, et al. Association of GSTM1, GSTT1 and GSTP1 polymorphisms with breast Cancer among Jordanian women. OncoTargets and Therapy. 2019;12:7757\u201365.","journal-title":"OncoTargets and Therapy"},{"key":"6490_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6425708","volume":"2019","author":"Laith N. AL-Eitan","year":"2019","unstructured":"AL-Eitan L, Rababa\u2019h D, Alghamdi M, et al. Role of four ABC transporter genes in Pharmacogenetic susceptibility to breast Cancer in Jordanian patients. J Oncol. 2019. Article ID 6425708, 8 pages https:\/\/doi.org\/10.1155\/2019\/6425708.","journal-title":"Journal of Oncology"},{"key":"6490_CR35","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.7314\/APJCP.2013.14.10.5625","volume":"14","author":"U Shaukat","year":"2013","unstructured":"Shaukat U, Ismail M, Mehmood N. Epidemiology, major risk factors and genetic predisposition for breast cancer in the Pakistani population. Asian Pac J Cancer Prev. 2013;14:5625\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"6490_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12881-019-0884-x","volume":"20","author":"L AL-Eitan","year":"2019","unstructured":"AL-Eitan L, Rababa\u2019h D, Alghamdi M, et al. Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population.L. BMC Med Genet. 2019;20:148.","journal-title":"BMC Med Genet"},{"issue":"4","key":"6490_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5339\/gcsp.2014.54","volume":"2014","author":"Ghazi O. Tadmouri","year":"2014","unstructured":"Tadmouri GO, Sastry KS, Chouchane L. Arab gene geography: from population diversities to personalized medical genomics. Glob Cardiol Sci Pract. 2014:394\u2013408. https:\/\/doi.org\/10.5339\/gcsp.2014.54.","journal-title":"Global Cardiology Science and Practice"},{"key":"6490_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/J.GENE.2018.02.011","volume":"651","author":"RM Ghali","year":"2018","unstructured":"Ghali RM, Al-Mutawa MA, Al-Ansari AK, et al. Differential association of ESR1 and ESR2 gene variants with the risk of breast cancer and associated features: a case-control study. Gene. 2018;651:194\u20139. https:\/\/doi.org\/10.1016\/J.GENE.2018.02.011.","journal-title":"Gene"},{"issue":"10","key":"6490_CR39","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1158\/1078-0432.CCR-03-0461","volume":"10","author":"SB Fox","year":"2004","unstructured":"Fox SB, Brown P, Han C, et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res. 2004;10(10):3521\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6490_CR40","first-page":"2935","volume":"17","author":"D Sa-Nguanraksa","year":"2016","unstructured":"Sa-Nguanraksa D, Suntiparpluacha M, Kulprom A, et al. Association of Estrogen Receptor Alpha and Interleukin 6 Polymorphisms with Lymphovascular Invasion, Extranodal Extension, and Lower Disease-Free Survival in Thai Breast Cancer Patients. APJCP. 2016;17(6):2935\u201340.","journal-title":"APJCP"},{"key":"6490_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.7555\/JBR.31.20160087","volume":"31","author":"X Hu","year":"2017","unstructured":"Hu X, Jiang L, Tang C, et al. Association of three single nucleotide polymorphisms of ESR1with breast cancer susceptibility: a meta-analysis. J Biomed Res. 2017;31:213\u201325. https:\/\/doi.org\/10.7555\/JBR.31.20160087.","journal-title":"J Biomed Res"},{"key":"6490_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-007-9497-8","volume":"106","author":"J Wang","year":"2007","unstructured":"Wang J, Higuchi R, Modugno F, et al. Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat. 2007;106:273\u201380. https:\/\/doi.org\/10.1007\/s10549-007-9497-8.","journal-title":"Breast Cancer Res Treat"},{"key":"6490_CR43","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/bcr2213","volume":"10","author":"W Tapper","year":"2008","unstructured":"Tapper W, Hammond V, Gerty S, et al. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res. 2008;10:R108. https:\/\/doi.org\/10.1186\/bcr2213.","journal-title":"Breast Cancer Res"},{"key":"6490_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","volume":"9","author":"CL Arteaga","year":"2012","unstructured":"Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16\u201332. https:\/\/doi.org\/10.1038\/nrclinonc.2011.177.","journal-title":"Nat Rev Clin Oncol"},{"key":"6490_CR45","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/1055-9965.EPI-08-1202","volume":"18","author":"JP Breyer","year":"2009","unstructured":"Breyer JP, Sanders ME, Airey DC, et al. Heritable variation of ERBB2 and breast cancer risk. Cancer Epidemiol Biomark Prev. 2009;18:1252\u20138. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-1202.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"6490_CR46","doi-asserted-by":"publisher","first-page":"e0119383","DOI":"10.1371\/journal.pone.0119383","volume":"10","author":"Y Li","year":"2015","unstructured":"Li Y, Wang X, Vural S, et al. Exome analysis reveals differentially mutated gene signatures of stage, Grade and Subtype in Breast Cancers. PLoS One. 2015;10:e0119383. https:\/\/doi.org\/10.1371\/journal.pone.0119383.","journal-title":"PLoS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6490-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6490-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6490-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:22:30Z","timestamp":1609201350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6490-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6490"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6490-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"1 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board (IRB) at Jordan University of Science and Technology with ethical code number (14\/78\/2014). Written informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1257"}}